| Literature DB >> 31496448 |
E J Morrison1, J Middleton1,2, S Lanza1, J E Cowen1, K Hewitt3, S L Walker4, M Nicholls3, J Rajan-Iyer3, J Fletcher1,2,3,4, J A Cassell1.
Abstract
Currently no national guidelines exist for the management of scabies outbreaks in residential or nursing care homes for the elderly in the United Kingdom. In this setting, diagnosis and treatment of scabies outbreaks is often delayed and optimal drug treatment, environmental control measures and even outcome measures are unclear. We undertook a systematic review to establish the efficacy of outbreak management interventions and determine evidence-based recommendations. Four electronic databases were searched for relevant studies, which were assessed using a quality assessment tool drawing on STROBE guidelines to describe the quality of observational data. Nineteen outbreak reports were identified, describing both drug treatment and environmental management measures. The quality of data was poor; none reported all outcome measures and only four described symptom relief measures. We were unable to make definitive evidence-based recommendations. We draw on the results to propose a framework for data collection in future observational studies of scabies outbreaks. While high-quality randomised controlled trials are needed to determine optimal drug treatment, evidence on environmental measures will need augmentation through other literature studies. The quality assessment tool designed is a useful resource for reporting of outcome measures including patient-reported measures in future outbreaks.Entities:
Keywords: Elderly medicine; infectious disease control; outbreaks; residential care; scabies
Mesh:
Year: 2019 PMID: 31496448 PMCID: PMC6805746 DOI: 10.1017/S0950268819001249
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Fig. 1.Outbreak measures in the timeline of a scabies outbreak in a RNC, including points in the diagnosis and management timeline where delay may occur.
Fig. 2.Flow of study selection at each stage from identification to final inclusion, including study numbers for both drug treatment and environmental management measures.
Summary of all studies included in the review, including outcome measures described in reports
| Author | Year | Country | Setting (number of scabies cases diagnosed) | Outcome measures | Drug treatment/environmental measures/both |
|---|---|---|---|---|---|
| Andersen | 2000 | Norway | Three nursing homes (24) | Number of cases before and after treatment, repeat cases | Both |
| Apap | 2012 | Malta | Residential home – treated in hospital (unknown) | Time from diagnosis to successful treatment of index case | Drug |
| Barkwell | 1997 | Canada | Long-term care facility (unknown) | Outbreak duration | Drug |
| Burns | 1987 | UK | Residential home (4) | Number of new cases after treatment | Both |
| Chan | 2000 | Hong Kong | Old-age home (9) | Time from symptoms to successful treatment of index case | Drug |
| Dannaoui | 1999 | France | Nursing home (7) | Treatment failure and repeat cases, outbreak duration | Both |
| De Beer | 2006 | South Africa | Long-term care facility (57) | Average duration of rash before treatment initiation, outbreak duration | Both |
| Hetland | 1987 | USA | Nursing home intermediate care facility (41) | Time from first symptoms to diagnosis, treatment failure rate | Both |
| Ladbury | 2012 | Netherlands | Four elderly care homes as part of a wider community outbreak (26) | Number of repeat cases or new cases after treatment | Drug |
| Millership | 2002 | UK | Homes for the elderly mentally ill (19) | Number of repeat cases or new cases after treatment | Drug |
| Moberg | 1984 | Sweden | Nursing home (14) | Treatment failure and repeat cases | Drug |
| Paasch | 2000 | Germany | Three residences for the elderly (252) | Treatment failure and repeat cases | Both |
| Papini | 1999 | Italy | Two nursing homes (91) | Outbreak duration | Drug |
| Parish | 1983 | USA | Three nursing homes (unknown) | Need for repeat treatment | Drug |
| Paules | 1993 | USA | Nursing home (6) | Treatment failure and repeat cases, repeat management measures, outbreak duration | Both |
| Sullivan | 1997 | Australia | Nursing home (33) | Treatment failure and repeat cases | Both |
| Van den Hoek | 2008 | Netherlands | Nursing home (5) | Cases remaining symptom free at 3 months | Both |
| Wilson | 2001 | USA | Long-term care geriatric facility (15) | Time to diagnosis, treatment failure | Drug |
| Yonkosky | 1990 | USA | Three nursing homes (202) | Treatment failure and repeat cases | Both |
Results of quality assessment tool adapted from the STROBE checklist for observational studies
| Outcome measure | Author | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | |
| Study design and outbreak identification: | |||||||||||||||||||
| 1. Description of study design | − | + | − | + | + | − | + | − | + | − | + | − | − | + | + | − | + | − | − |
| 2. Description of setting | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| 3. Description of how outbreak identified | + | + | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | − | − |
| 4. Method of case diagnosis described | + | + | − | + | + | + | + | + | − | + | + | + | + | + | + | + | + | + | + |
| 5. Number of individuals assessed for scabies | + | − | − | + | − | + | − | + | − | − | + | + | + | + | + | + | − | − | + |
| 6. Characteristics of cases (demographic, clinical, social) | − | − | + | + | − | − | + | − | + | + | + | + | + | − | + | − | + | + | + |
| 7. Number of cases reported | + | − | − | + | + | + | + | + | + | + | + | + | + | − | + | + | + | + | + |
| Efficacy of management measure: | |||||||||||||||||||
| 8. Full description of treatment including who treated and why | + | − | + | + | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| 9. Full description of EMMs implemented | + | − | − | + | − | + | + | + | − | − | − | + | − | − | + | + | + | − | + |
| 10. Number of repeat cases observed after treatment | + | − | + | + | − | + | + | + | + | + | + | + | − | − | + | + | + | + | + |
| 11. Number of new cases observed after treatment | + | − | − | + | − | + | + | + | + | + | + | + | − | − | + | + | + | + | + |
| 12. Adverse events or side effects reported | − | − | + | − | − | + | − | − | − | + | + | + | − | + | − | + | − | − | + |
| Management delay: | |||||||||||||||||||
| 13. Date of outbreak identification reported | + | − | + | − | − | + | + | − | + | + | − | − | + | − | + | − | + | + | + |
| 14. Date of mass treatment±environmental management implementation | − | − | + | − | − | + | + | + | − | + | − | − | − | − | + | − | + | − | − |
| 15. Date outbreak declared over reported | + | − | + | − | − | + | + | − | + | + | − | − | + | − | + | − | + | + | − |
| Patient Experience measures: | |||||||||||||||||||
| 16. PROMs/PREMs reported (severity/duration of itch, quality of sleep, secondary infection etc.) | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| 17. Description of symptomatic treatment given | − | − | + | − | + | − | − | − | − | − | − | + | − | + | − | − | − | − | − |
| Total | 11 | 4 | 9 | 11 | 6 | 13 | 13 | 10 | 10 | 12 | 11 | 12 | 9 | 8 | 14 | 10 | 13 | 9 | 11 |
+ Represents criteria achieved. − Represents criteria not achieved.
Summary of drug treatments implemented in reports. Alternative treatments used due to new cases arising following treatment or unresolved cases. Note some RNCs reported the use of different drug treatments for different residences affected
| Number of reports in which treatment used first line | Number of reports in which alternative needed | Alternative treatment used | |
|---|---|---|---|
| Topical treatments | |||
| Lindane | 7 | 4 | Ivermectin, crotamiton, permethrin |
| Permethrin 5% cream | 4 | 1 | Ivermectin |
| Benzyl benzoate | 3 | 1 | Permethrin |
| Crotamiton | 3 | 2 | Ivermectin, permethrin |
| Tenutex | 1 | 0 | |
| Allethrin spray | 1 | 0 | Ivermectin for crusted scabies |
| Topical treatment in combination with oral treatment | |||
| Lindane + ivermectin | 1 | 1 | Ivermectin + permethrin |
| Malathion, permethrin + ivermectin | 1 | 0 | |
| Permethrin + ivermectin | 1 | 0 | |
| Oral treatment only | |||
| Ivermectin | 3 | 0 |
Tenutex = DDT 0.5%, disulphiram 2%, benzyl benzoate 22.5%; commercial purified form of GBHC (gamma benzene hexachloride) is lindane, therefore results combined.
Staff and contacts were treated with topical permethrin in all three reports.
Summary of environmental management measures implemented in reports
| Environmental management measure | Author | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | |
| Isolation of cases | + | + | + | + | − | − | − | − | − | − |
| Use of gowns±gloves | + | + | − | + | + | + | − | − | − | − |
| Handwashing between care | + | − | − | − | − | − | − | − | − | − |
| Long sleeves worn | + | − | − | + | − | − | − | − | − | − |
| Washing of clothes | + | − | + | + | + | + | + | + | + | + |
| Spray or disinfection of environment | + | + | − | + | + | + | + | + | + | + |
| Upholstery/bed linen washed, frozen or bagged | + | − | + | + | + | + | + | − | + | |
| Visitor ban | − | − | − | + | − | − | − | − | − | − |
| Suspend admissions | − | − | − | + | + | − | − | − | − | − |
+ Represents measure implemented. − Represents measure not implemented or not described.
Where information regarding a measure was not provided in the text, the report was scored as not achieving said point (−).